410 Medical Clinches $14M Series B Funding to Accelerate LifeFlow® PLUS Revolution in Critical Care

410 Medical is thrilled to announce a major milestone in our journey to revolutionize critical care—with the successful raise of $14,000,000 to further the development and market presence of our cutting-edge product, LifeFlow® PLUS.

As a dedicated medical device company, we specialize in creating innovative solutions that empower clinicians to improve care for critically ill patients.

LifeFlow® PLUS, our recently approved device, is specifically designed to enhance both the speed and efficiency of volume resuscitation, addressing critical challenges in treating life-threatening conditions such as sepsis, hemorrhage, and cardiac arrest.

This significant funding will enable us to accelerate the deployment of LifeFlow® PLUS into healthcare facilities across the nation and beyond.

The infusion of capital will support the scaling of our production capabilities, the expansion of our clinical research efforts, and the establishment of key strategic partnerships that are essential to broadening access to this lifesaving technology.

Additionally, we are committed to further refining our product to ensure it remains the gold standard in rapid resuscitation solutions, thereby providing frontline medical professionals with the tools they need to save lives when every second counts.

At 410 Medical, our focus remains steadfast on innovation and quality, and this latest round of investments reaffirms our shared vision with investors and stakeholders to drive transformative change in critical care.

We are excited to embark on this next chapter, confident that the additional resources will translate into tangible benefits for patients and clinicians alike, ultimately saving more lives through improved and efficient care delivery.